R

Retension Pharmaceuticals, Inc.

RTSNPriced

Retension Pharmaceuticals, Inc. · Nasdaq Capital Market · latest filing 2026-10-13

Report source
One-minute decisionBASIC RESEARCH424B4 · Coverage 76%

Retension prices its clinical-stage IPO at $12, with substantial execution, funding and disclosure risks.

As of the October 9, 2026 Form 424B4, Retension disclosed a $12 IPO for 3.75 million primary shares and an expected October 13 delivery.

Where does the money go?Awaiting verification424B4 · 2026-10-09
Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointExpected delivery on or about October 13, 2026; completion and trading commencement are unconfirmed.424B4 · 2026-10-09

Capital destination

Awaiting verification

424B4 · 2026-10-09

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗
Next checkExpected delivery on or about October 13, 2026; completion and trading commencement are unconfirmed.
Latest filing2026-10-13

Capital destination

Awaiting verification

424B4 · 2026-10-09

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗
BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters
NOT YET DISCLOSED

Names not yet published

Fully diluted valuation bridge

Awaiting verification
Source ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · 424B4 ↗

Holder data awaits verification

Post-offering aggregate insider, director and greater-than-5% ownership is disclosed at approximately 16.2%; voting percentages are not supplied. · 2026-10-09

Post-offering aggregate insider, director and greater-than-5% ownership is disclosed at approximately 16.2%; voting percentages are not supplied.

One disclosed holder; not a complete ownership distribution.Check the source · 424B4 ↗

Conditional lock-up timeline

Awaiting verification
Source ↗

Financial quality and runway

Awaiting verification
Source ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

SEC EDGAR

424B4

2026-10-13

Open SEC filing ↗